Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

2015 pharmaceutical market: reaction to the crisis

Tuesday, March 3, 2015

On March 2nd the 10th Anniversary Conference "Pharmaceutical Business in Russia: a promising scenario of the pharmaceutical market in 2015", organized by “Infor-media Russia” took p[lace in Moscow. RNC Pharma presented the evaluation of current situation in the pharmaceutical industry, and shared the analysis of possible crisis consequences for the market and possible regulatory impact of anti-crisis measures proposed by Government.

The acute phase of the crisis took place in late 2014, and this year market participants will have to deal with the crisis consequences in the economy. As shows the experience of previous years, the central role in this process will be taken by active implementation of government anti-crisis measures.

Among them a special role should play the resolution on the access restriction of foreign drugs to State procurement market - the so-called "odd man out" norm. According to a study, conducted by RNC Pharma, Russian companies (as well as market players from SES) may pretend for 47,4% of Russian pharmaceutical market. At the same time, so far, the process of drugs production localization by foreign companies’ side in Russia cannot seriously change the situation.

Another initiative, which has the most serious consequences for foreign companies’ business in the pharmaceutical market, may be drugs parallel imports permission. Experience of other countries shows that the share of goods, imported through alternative channels may be from 10% to 20%. In terms of value, this corresponds to the amount of 50-100 billion rubles, so the turnover decrease of largest foreign pharmaceutical companies could reach this level.

Slide show with a presentation is available by the link.